Author

List of Dr. Christine Boers-Doets’ Key Publications

• Boers CB: EGFR-inhibitors: Do you give the right advices? Skin reactions by epidermal growth factor receptor inhibitors [EGFR-remmers: geef jij de juiste adviezen? Huidreacties door epidermale groeifactor receptor-remmers]. Oncologica. 2007;2:36-39
• Koldenhoff JJ, Boers-Doets CB: Book Chapter 4.9 Skin Toxicity; in Huisman C, Mallo H, van Riel C, Hulshoff A, van Steijn J, Immuno-/targeted therapy in solid and hematology care [Immuno-/targeted therapie in de hemato-/oncologische zorg]. ISBN: 9789035230064. Reed Elsevier. 2008;78-87
• Boers CB, Galimont AFS, Gelderblom AJ: Skin reactions due to Erbitux treatment, patient information [Huidreacties bij een behandeling met Erbitux] provided by Merk Serono Netherlands 2009, revised edition of the patient information cards Skin reaction October 4th 2006
• Ouwerkerk J, Boers-Doets CB: Focus on eye changes [Oog voor oogafwijkingen]. Nursing. July/August, 2008;22-24
• Boers-Doets CB, Langenhoff JM, Brakenhoff JAC, et al.: Dermatological side effect interventions for targeted cancer treatment untangled: A systematic review. EJC supplements. 2009;7:185, poster presentation
• Ouwerkerk J, Boers-Doets CB: Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010;14(4):337-49. Epub 2010 May 23
• Boers-Doets CB, Ouwerkerk J, Schrama NAWP, Galimont AFS: Management skin-, hair-, nail-, and eye reactions targeted therapy: comprehensive – not complex [Management huid-, haar- nagel- en oogreacties targeted therapie: veelomvattend - maar niet complex]. Oncologica. 2010;2: 21-24 
• Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x. 
• Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1.
• Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A: Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group. Eur J Oncol Nurs. 2012 Apr;16(2):172-84. Epub 2011 Jun 8.
• Boers-Doets C, Lacouture M, Langenhoff J, van Zuuren EJ, Stijnen T, Brakenhoff J, Ouwerkerk J, Galimont A, Bro W, Nortier H: Interventions for skin reactions associated with targeted anticancer treatments. Cochrane Database of Systematic Reviews. 2011, Issue 7. Art. No.: CD009236. DOI: 10.1002/14651858.CD009236.
• Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist. 2012;17(1):135-44. doi: 10.1634/theoncologist.2011-0111. Epub 2011 Dec 29.
• Raber-Durlacher JE, Boers-Doets CB, de Graeff A: Oral complaints; Side effects of new targeted cancer therapies [Mondklachten; Bijwerkingen van nieuwe doelgerichte kankertherapieen]. Tandartspraktijk. 2012;33(9):26-31.
• Boers-Doets CB: Skin toxicities caused by targeted therapies. Cancer World. 2013 March-April: 37-43.
• Boers-Doets CB, Gelderblom H, Lacouture ME, Bredle JM, Epstein JB, Schrama NA, Gall H, Ouwerkerk J, Brakenhoff JA, Nortier JW, Kaptein AA. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. Eur J Oncol Nurs. 2013 Dec;17(6):802-7. doi: 10.1016/j.ejon.2013.03.004. Epub 2013 Apr 6.
• Boers-Doets CB, Gelderblom H, Lacouture ME, Epstein JB, Nortier JW, Kaptein AA. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer. 2013 Jul;21(7):1919-26. doi: 10.1007/s00520-013-1752-4. Epub 2013 Feb 17.
• Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013 Oct;21(10):2933-48. doi: 10.1007/s00520-013-1896-2. Epub 2013 Aug 14.
• Boers-Doets CB, Lalla RV: The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Support Care Cancer. 2013;21 (S1),S140
• Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, Bossi P, Escalante C, Brennan MT; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer. 2013 Nov;21(11):3243-54. doi: 10.1007/s00520-013-1821-8. Epub 2013 May 2.
• Boers-Doets CB, Lacouture ME: Dermatologic Events in Oncology: How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life. http://issuu.com/ascopost/docs/tap_vol_4_issue_20. ASCO Post. 2013 Dec 15;4(20):70-71 
• Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141.
• Boers-Doets CB, Kaptein AA, Brakenhoff JAC, Nortier, JWR, Gelderblom H: Targeted therapy associated mucocutaneous reactions – the BeCet and the COMTT study [Doelgerichte therapie geassocieerde mucocutane bijwerkingen – de BeCet en de COMTT studie]. NTvO. 2013;(10)8:343-47.
• De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014 Mar;22(3):837-46. doi: 10.1007/s00520-013-2085-z. Epub 2013 Dec 14.
• Kaehler KC, Boers-Doets CB, Lacouture ME, Hauschild A. Chapter 21: Miscellaneous Reactions. In Lacouture ME, et al: Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients. Wiley-Blackwell. ISBN: 9780470621882. Published: 31 January 2014. p.224-33.
• Boers-Doets CB. The Target System - Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. First edition. 2014 IMPAQTT. ISBN/EAN: 978-94-92070-00-5
• Bryce J, Boers-Doets CB. Non-rash dermatologic adverse events related to targeted therapies. Semin Oncol Nurs. 2014 Aug;30(3):155-68. doi: 10.1016/j.soncn.2014.05.003.
• Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up†. Ann Oncol. 2015 Sep;26 Suppl 5:v139-51. doi: 10.1093/annonc/mdv202. Epub 2015 Jul 4.
• Clabbers JM, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJ, Kaptein AA. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.
• Ruiz JN, Belum VR, Boers-Doets CB, Kamboj M, Babady NE, Tang YW, Valdez TA, Lacouture ME. Nasal vestibulitis due to targeted therapies in cancer patients. Support Care Cancer. 2015 Aug;23(8):2391-8. doi: 10.1007/s00520-014-2580-x. Epub 2015 Jan 22.
• Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. Support Care Cancer. 2015 Aug;23(8):2231-44. doi: 10.1007/s00520-014-2564-x. Epub 2015 Jan 7.
• R.V. Lalla, C. B. Boers-Doets ESMO Handbook on Rehabilitation Issues During Cancer Treatment and Follow-Up. Chapter 5 - Mucocutaneous Changes. https://oncologypro.esmo.org/education-library/handbooks/rehabilitation-issues-during-cancer-treatment-and-follow-up 
• Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192.
• Carrozzo M, Eriksen JG, Bensadoun RJ, Boers-Doets CB, Lalla RV, Peterson DE. Oral Mucosal Injury Caused by Targeted Cancer Therapies. J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53). pii: lgz012. doi: 10.1093/jncimonographs/lgz012. PMID: 31425602